The Lancet Global Health | Symptom-Agnostic Endpoints in TB Vaccine Efficacy Trials
10 November 2026
Health Policy publication in The Lancet Global Health
TB vaccine prevention-of-disease efficacy trials traditionally rely on symptom-triggered case detection. This approach captures only a subset of bacteriologically confirmed disease and can miss cases that occur between scheduled trial visits or outside trial procedures, slowing endpoint accrual and complicating interpretation of results. At the same time, the diagnostic landscape for TB is changing rapidly. Advances, including near-point-of-care (NPOC) molecular assays using sputum and non-sputum specimens, portable chest radiography with computer-aided detection, and digital tools for decentralised monitoring, now make symptom-agnostic screening strategies increasingly feasible in large clinical trials. A 2026 WHO policy recommending the use of NPOC molecular diagnostics for TB further highlights the relevance of these approaches.
A Health Policy paper, published in The Lancet Global Health, outlined a framework for integrating symptom-agnostic screening into TB vaccine efficacy trials and reviewed emerging diagnostic technologies that could enable this transition.
Access the full publication here.
Source: The Lancet Global Health
